Mats Jerkeman
Professor of Clinical Oncology
Lund University / Skane University Hospital · Lund, Sweden
Led the Nordic Lymphoma Group's MCL trials and co-led the TRIANGLE trial, the largest randomized MCL trial ever, evaluating ibrutinib in frontline MCL.
Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma.
International journal of cancer · Apr 1, 2026
Survival in mantle cell lymphoma patients burdened by a second primary malignancy.
Leukemia & lymphoma · Mar 1, 2026
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Haematologica · Oct 30, 2025
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lancet (London, England) · Oct 25, 2025
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
HemaSphere · Oct 1, 2025
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.
Blood advances · Sep 9, 2025
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study.
Blood neoplasia · Aug 1, 2025
Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma.
Genes · May 25, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial.
HemaSphere · Mar 1, 2025
Limited stage mantle cell lymphoma: A real-world study of primary treatment and prognosis in Sweden 2006-2018.
HemaSphere · Jan 1, 2025
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older.
Blood cancer journal · Dec 19, 2024
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood · Aug 29, 2024
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.
Blood advances · Aug 27, 2024
Infections in patients with mantle cell lymphoma.
HemaSphere · Jul 1, 2024
Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients.
Cancers · Jun 21, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet (London, England) · May 25, 2024
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Blood advances · Jan 23, 2024
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Jan 1, 2024